<?xml version='1.0' encoding='utf-8'?>
<document id="32222808"><sentence text="Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma." /><sentence text="The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL)"><entity charOffset="141-157" id="DDI-PubMed.32222808.s2.e0" text="cyclophosphamide" /><entity charOffset="159-170" id="DDI-PubMed.32222808.s2.e1" text="doxorubicin" /><entity charOffset="176-186" id="DDI-PubMed.32222808.s2.e2" text="prednisone" /><entity charOffset="190-195" id="DDI-PubMed.32222808.s2.e3" text="G-CHP" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e0" e2="DDI-PubMed.32222808.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e0" e2="DDI-PubMed.32222808.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e0" e2="DDI-PubMed.32222808.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e0" e2="DDI-PubMed.32222808.s2.e3" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e1" e2="DDI-PubMed.32222808.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e1" e2="DDI-PubMed.32222808.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e1" e2="DDI-PubMed.32222808.s2.e3" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e2" e2="DDI-PubMed.32222808.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s2.e2" e2="DDI-PubMed.32222808.s2.e3" /></sentence><sentence text=" We report the pharmacokinetics (PK) and drug-drug interaction (DDI) for pola" /><sentence text="" /><sentence text="Six or eight cycles of pola 1" /><sentence text="0-1" /><sentence text="8 mg/kg were administered intravenously every 3 weeks (q3w) with R/G-CHP"><entity charOffset="67-71" id="DDI-PubMed.32222808.s7.e0" text="G-CHP" /></sentence><sentence text=" Exposures of pola [including antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE] and R/G-CHP were assessed by non-compartmental analysis and/or descriptive statistics with cross-cycle comparisons to cycle 1 and/or after multiple cycles"><entity charOffset="50-73" id="DDI-PubMed.32222808.s8.e0" text="monomethyl auristatin E" /><entity charOffset="75-81" id="DDI-PubMed.32222808.s8.e1" text="acMMAE" /><entity charOffset="112-117" id="DDI-PubMed.32222808.s8.e2" text="G-CHP" /><pair ddi="false" e1="DDI-PubMed.32222808.s8.e0" e2="DDI-PubMed.32222808.s8.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s8.e0" e2="DDI-PubMed.32222808.s8.e1" /><pair ddi="false" e1="DDI-PubMed.32222808.s8.e0" e2="DDI-PubMed.32222808.s8.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s8.e1" e2="DDI-PubMed.32222808.s8.e1" /><pair ddi="false" e1="DDI-PubMed.32222808.s8.e1" e2="DDI-PubMed.32222808.s8.e2" /></sentence><sentence text=" Pola was evaluated as a potential victim and perpetrator of a PK drug-drug interaction with R/G-CHP"><entity charOffset="95-99" id="DDI-PubMed.32222808.s9.e0" text="G-CHP" /></sentence><sentence text=" Population PK (popPK) analysis assessed the impact of prior treatment status (naïve vs" /><sentence text=" relapsed/refractory) on pola PK" /><sentence text="" /><sentence text="Pola PK was similar between treatment arms and independent of line of therapy" /><sentence text=" Pola PK was dose proportional from 1" /><sentence text="0 to 1" /><sentence text="8 mg/kg with R/G-CHP"><entity charOffset="15-19" id="DDI-PubMed.32222808.s16.e0" text="G-CHP" /></sentence><sentence text=" Geometric mean volume of distribution and clearance of acMMAE ranged from 57" /><sentence text="3 to 95" /><sentence text="6 mL/kg and 12" /><sentence text="7 to 18" /><sentence text="2 mL/kg/day, respectively" /><sentence text=" acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week)" /><sentence text=" Unconjugated MMAE exhibited formation rate-limited kinetics" /><sentence text=" Exposures of pola with R/G-CHP were similar to those in the absence of CHP; exposures of R/G-CHP in the presence of pola were comparable to those in the absence of pola"><entity charOffset="72-75" id="DDI-PubMed.32222808.s24.e0" text="CHP" /><entity charOffset="26-28" id="DDI-PubMed.32222808.s24.e1" text="G-CHP" /><entity charOffset="92-94" id="DDI-PubMed.32222808.s24.e2" text="G-CHP" /><entity charOffset="28-30" id="DDI-PubMed.32222808.s24.e3" text="CHP" /><entity charOffset="94-96" id="DDI-PubMed.32222808.s24.e4" text="CHP" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e1" e2="DDI-PubMed.32222808.s24.e1" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e1" e2="DDI-PubMed.32222808.s24.e3" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e1" e2="DDI-PubMed.32222808.s24.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e1" e2="DDI-PubMed.32222808.s24.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e1" e2="DDI-PubMed.32222808.s24.e4" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e3" e2="DDI-PubMed.32222808.s24.e3" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e3" e2="DDI-PubMed.32222808.s24.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e3" e2="DDI-PubMed.32222808.s24.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e3" e2="DDI-PubMed.32222808.s24.e4" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e0" e2="DDI-PubMed.32222808.s24.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e0" e2="DDI-PubMed.32222808.s24.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e0" e2="DDI-PubMed.32222808.s24.e4" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e2" e2="DDI-PubMed.32222808.s24.e2" /><pair ddi="false" e1="DDI-PubMed.32222808.s24.e2" e2="DDI-PubMed.32222808.s24.e4" /></sentence><sentence text="" /><sentence text="Pola PK was well characterized with no clinically meaningful DDIs with R/G-CHP"><entity charOffset="73-75" id="DDI-PubMed.32222808.s26.e0" text="G-CHP" /><entity charOffset="75-77" id="DDI-PubMed.32222808.s26.e1" text="CHP" /><pair ddi="false" e1="DDI-PubMed.32222808.s26.e0" e2="DDI-PubMed.32222808.s26.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s26.e0" e2="DDI-PubMed.32222808.s26.e1" /></sentence><sentence text=" Findings are consistent with previous studies of pola + R/G, and support pola + R/G-CHP use in previously untreated diffuse large B-cell lymphoma"><entity charOffset="83-85" id="DDI-PubMed.32222808.s27.e0" text="G-CHP" /><entity charOffset="85-87" id="DDI-PubMed.32222808.s27.e1" text="CHP" /><pair ddi="false" e1="DDI-PubMed.32222808.s27.e0" e2="DDI-PubMed.32222808.s27.e0" /><pair ddi="false" e1="DDI-PubMed.32222808.s27.e0" e2="DDI-PubMed.32222808.s27.e1" /></sentence><sentence text="" /></document>